Recursion Pharmaceuticals (RXRX) Competitors $4.91 -0.02 (-0.41%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$4.93 +0.02 (+0.41%) As of 09/19/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RXRX vs. GRFS, RYTM, ABVX, CYTK, LEGN, AXSM, NUVL, RNA, MRUS, and TGTXShould you be buying Recursion Pharmaceuticals stock or one of its competitors? The main competitors of Recursion Pharmaceuticals include Grifols (GRFS), Rhythm Pharmaceuticals (RYTM), Abivax (ABVX), Cytokinetics (CYTK), Legend Biotech (LEGN), Axsome Therapeutics (AXSM), Nuvalent (NUVL), Avidity Biosciences (RNA), Merus (MRUS), and TG Therapeutics (TGTX). These companies are all part of the "pharmaceutical products" industry. Recursion Pharmaceuticals vs. Its Competitors Grifols Rhythm Pharmaceuticals Abivax Cytokinetics Legend Biotech Axsome Therapeutics Nuvalent Avidity Biosciences Merus TG Therapeutics Grifols (NASDAQ:GRFS) and Recursion Pharmaceuticals (NASDAQ:RXRX) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends. Is GRFS or RXRX more profitable? Grifols has a net margin of 0.00% compared to Recursion Pharmaceuticals' net margin of -1,004.91%. Grifols' return on equity of 0.00% beat Recursion Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets GrifolsN/A N/A N/A Recursion Pharmaceuticals -1,004.91%-76.09%-54.29% Which has more risk and volatility, GRFS or RXRX? Grifols has a beta of 0.64, indicating that its stock price is 36% less volatile than the S&P 500. Comparatively, Recursion Pharmaceuticals has a beta of 0.91, indicating that its stock price is 9% less volatile than the S&P 500. Do insiders & institutionals hold more shares of GRFS or RXRX? 89.1% of Recursion Pharmaceuticals shares are held by institutional investors. 0.2% of Grifols shares are held by company insiders. Comparatively, 8.4% of Recursion Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has stronger earnings & valuation, GRFS or RXRX? Grifols has higher revenue and earnings than Recursion Pharmaceuticals. Recursion Pharmaceuticals is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGrifols$7.81B0.86$169.80M$1.178.32Recursion Pharmaceuticals$58.84M36.23-$463.66M-$1.78-2.76 Does the media favor GRFS or RXRX? In the previous week, Recursion Pharmaceuticals had 2 more articles in the media than Grifols. MarketBeat recorded 4 mentions for Recursion Pharmaceuticals and 2 mentions for Grifols. Recursion Pharmaceuticals' average media sentiment score of 0.80 beat Grifols' score of 0.76 indicating that Recursion Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Grifols 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Recursion Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate GRFS or RXRX? Grifols presently has a consensus target price of $10.30, suggesting a potential upside of 5.75%. Recursion Pharmaceuticals has a consensus target price of $7.25, suggesting a potential upside of 47.66%. Given Recursion Pharmaceuticals' higher possible upside, analysts clearly believe Recursion Pharmaceuticals is more favorable than Grifols.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Grifols 0 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.60Recursion Pharmaceuticals 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.40 SummaryGrifols beats Recursion Pharmaceuticals on 9 of the 17 factors compared between the two stocks. Get Recursion Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RXRX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RXRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RXRX vs. The Competition Export to ExcelMetricRecursion PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.13B$2.53B$5.77B$10.45BDividend YieldN/A55.05%5.61%4.58%P/E Ratio-2.7623.0280.5026.81Price / Sales36.23480.45458.4992.96Price / CashN/A172.2337.6661.43Price / Book1.885.3515.756.39Net Income-$463.66M$32.95M$3.30B$271.80M7 Day Performance1.66%0.90%5.35%3.51%1 Month Performance2.72%4.71%7.28%9.58%1 Year Performance-27.79%-2.98%80.79%28.53% Recursion Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RXRXRecursion Pharmaceuticals2.2842 of 5 stars$4.91-0.4%$7.25+47.7%-27.8%$2.13B$58.84M-2.76400High Trading VolumeGRFSGrifols3.8273 of 5 stars$9.88-1.6%$10.30+4.3%+8.8%$6.90B$7.81B8.4423,822RYTMRhythm Pharmaceuticals3.2569 of 5 stars$96.22-1.7%$101.57+5.6%+81.9%$6.50B$156.29M-31.97140Positive NewsABVXAbivax2.7316 of 5 stars$84.01-2.3%$99.43+18.4%+628.3%$6.50BN/A0.0061Short Interest ↑CYTKCytokinetics4.2411 of 5 stars$51.13-4.1%$75.38+47.4%-9.5%$6.38B$18.47M-10.03250Trending NewsLEGNLegend Biotech3.1553 of 5 stars$33.11-2.1%$74.22+124.2%-29.9%$6.24B$627.24M-37.632,609Positive NewsAXSMAxsome Therapeutics4.8582 of 5 stars$118.42-3.7%$177.86+50.2%+21.0%$6.14B$495.03M-23.36380Insider TradeAnalyst RevisionNUVLNuvalent3.0113 of 5 stars$80.47-2.1%$120.91+50.3%-29.0%$5.93BN/A-16.4240Positive NewsInsider TradeRNAAvidity Biosciences2.0836 of 5 stars$44.74+9.0%$68.33+52.7%-7.7%$5.28B$10.90M-12.57190Trending NewsAnalyst ForecastAnalyst RevisionHigh Trading VolumeMRUSMerus2.8294 of 5 stars$69.58-0.3%$88.75+27.6%+37.3%$5.28B$36.13M-12.6537Analyst ForecastHigh Trading VolumeTGTXTG Therapeutics4.2894 of 5 stars$32.16-0.9%$46.25+43.8%+31.3%$5.15B$454.07M86.92290Trending NewsAnalyst ForecastAnalyst Revision Related Companies and Tools Related Companies Grifols Competitors Rhythm Pharmaceuticals Competitors Abivax Competitors Cytokinetics Competitors Legend Biotech Competitors Axsome Therapeutics Competitors Nuvalent Competitors Avidity Biosciences Competitors Merus Competitors TG Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RXRX) was last updated on 9/21/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Recursion Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Recursion Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
